Digital Mental Health ’s Unstable Dichotomy
This Viewpoint discusses the unacknowledged risks and harms and unrealized clinical benefits of digital mental wellness and health technologies and offers suggestions for ways to catalyze the next phase of these technologies by focusing on safety, evidence, and engagement. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 17, 2024 Category: Psychiatry Source Type: research
Examining Sex Differences in Autism Heritability
This cohort study analyzes sex-specific differences in heritability of autism spectrum disorder among individuals in Sweden. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 17, 2024 Category: Psychiatry Source Type: research
Prevalence of Mental Health Disorders Among Individuals Experiencing Homelessness
This systematic review and meta-analysis assesses the prevalence of mental health disorders among people experiencing homelessness. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 17, 2024 Category: Psychiatry Source Type: research
Pain Scores as Secondary Outcomes —Opioid Reduction Studies—Reply
In Reply In the response from Hogans to our study describing the effects of telehealth Mindfulness-Oriented Recovery Enhancement (MORE), they note that baseline Brief Pain Inventory (BPI) scores differed from the initial ecological momentary assessment (EMA) rating of pain and question whether this discrepancy relates to either a pain spike in the intervention group or excessive variance. It is unlikely that any potential increase in pain was due to MORE, given that MORE significantly reduced pain in our pilot study in the same population of patients with pain and opioid use disorder receiving methadone treatment, and MORE...
Source: JAMA Psychiatry - April 17, 2024 Category: Psychiatry Source Type: research
Pain Scores as Secondary Outcomes —Opioid Reduction Studies
To the Editor In their article describing the effects of telehealth mindfulness on opioid use reduction, Cooperman and colleagues include pain as a secondary outcome. Pain is assessed at baseline, 8 weeks, and 16 weeks using the Brief Pain Inventory (BPI), and twice daily throughout using Ecological Momentary Assessment (EMA). At baseline, BPI pain scores are 5.1 and 5.2 (intervention and comparison, respectively); initial EMA pain scores are 5.79 and 5.19, respectively. This potentially suggests either a pain spike in the intervention group or excessive variance. After treatment, EMA pain scores are 5.17 and 4.97 respecti...
Source: JAMA Psychiatry - April 17, 2024 Category: Psychiatry Source Type: research
Sex Differences in Autism Heritability and Likelihood
Autism is a neurodevelopmental condition that includes difficulties with communication, social interaction, and adjusting to unexpected change, alongside differences in narrow interests, unusually repetitive behavior, and sensory hypersensitivity. Some differences are strengths, such as excellent attention to detail. After years of multidisciplinary research, autism diagnosis still relies on behavioral assessments and no reliable biomarker has been consistently associated with the condition. Autistic people are very heterogeneous in their range of behaviors, cognitive skills, co-occurring conditions, and levels of disabili...
Source: JAMA Psychiatry - April 17, 2024 Category: Psychiatry Source Type: research
Essentials of Informed Consent to Psychedelic Medicine
This Special Communication discusses the essential elements of designing and implementing informed consent practices for psychedelic medicine. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Adolescent Media Use and Psychotic Experiences
This cohort study examines data for participants of the Qu ébec Longitudinal Study of Child Development to analyze adolescent trajectories of media use for associations with psychotic experiences during early adulthood. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Treating Bipolar Depression Using Psilocybin —Validity Threats Regarding Efficacy and Safety—Reply
In Reply We thank Fried et al for their thoughtful remarks about our article. The first issue they raised concerned the description of our study as a nonrandomized controlled trial. This could be problematic, as there was no comparator group or other control for non-specific effects. However, the nature of the study design was clearly described in the article and the accompanying editorial, which stated, “Aaronson and colleagues present an important step forward in this single-arm open-label study of psilocybin in patients with bipolar II depression.” We elected to use the phrase “controlled trial” to reflect the s...
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Treating Bipolar Depression Using Psilocybin —Validity Threats Regarding Efficacy and Safety
To the Editor According to the study protocol, the recently published study by Aaronson et al was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Trends in Deaths of Despair by Race and Ethnicity From 1999 to 2022
This cross-sectional study examines trends in deaths of despair by race and ethnicity from 1999 to 2022. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Informed Consent to Psychedelic Treatment —A Work in Progress
Psychedelic compounds appear to be moving toward approval for clinical use, with early studies suggesting therapeutic efficacy for conditions ranging from depression to alcohol use disorder to traumatic brain injury. However, obtaining meaningful informed consent to psychedelic treatment will be challenging, given the unique effects of the drugs —including what are often described as the ineffable elements of the psychedelic experience, such as ego dissolution. Although some commentators have suggested that informed consent to psychedelic treatment, in the usual sense of that term, is simply unattainable, a growing conse...
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Error in Title and Text
This article was corrected online. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 10, 2024 Category: Psychiatry Source Type: research
Medicaid Reentry Section 1115 Demonstration Opportunity
This Viewpoint explains the Medicaid Reentry Section 1115 Demonstration Opportunity of April 2023 and recommends strategies to optimize this opportunity for community connection and mental health care. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 3, 2024 Category: Psychiatry Source Type: research
A Dynamical Systems View of Psychiatric Disorders —Practical Implications
This narrative review, the second of 2 parts about a new approach to the diagnosis and treatment of psychiatric disorders that is based on dynamical systems theory, describes the implications of evidence for the practical applicability of this theory and its quantitative tools. (Source: JAMA Psychiatry)
Source: JAMA Psychiatry - April 3, 2024 Category: Psychiatry Source Type: research
